{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:05:03Z","timestamp":1784099103293,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00198-020-05701-9","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T05:06:58Z","timestamp":1605589618000},"page":"173-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9905-461X","authenticated-orcid":false,"given":"N.","family":"Binkley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Orwoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-6385","authenticated-orcid":false,"given":"R.","family":"Chapurlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"B. L.","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0963-044X","authenticated-orcid":false,"given":"B. B.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Giezek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-7935","authenticated-orcid":false,"given":"A. C.","family":"Santora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"5701_CR1","first-page":"65","volume":"7","author":"T Willson","year":"2015","unstructured":"Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J (2015) The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol 7:65\u201376","journal-title":"Clin Epidemiol"},{"issue":"Suppl 2","key":"5701_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","volume":"16","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3\u2013S7","journal-title":"Osteoporos Int"},{"key":"5701_CR3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"5701_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.2009.1462","volume":"302","author":"CA Brauer","year":"2009","unstructured":"Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573\u20131579","journal-title":"JAMA"},{"key":"5701_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrrheum.2011.77","volume":"7","author":"AG Costa","year":"2011","unstructured":"Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP (2011) Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 7:447\u2013456","journal-title":"Nat Rev Rheumatol"},{"key":"5701_CR6","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW, Denosumab Phase 3 Bone Histology Study Group (2010) Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25:2256\u20132265","journal-title":"J Bone Miner Res"},{"key":"5701_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/jbmr.1475","volume":"27","author":"PJ Masarachia","year":"2012","unstructured":"Masarachia PJ, Pennypacker BL, Pickarski M, Scott KR, Wesolowski GA, Smith SY, Samadfam R, Goetzmann JE, Scott BB, Kimmel DB, Duong LT (2012) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27:509\u2013523","journal-title":"J Bone Miner Res"},{"key":"5701_CR8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00198-009-1129-1","volume":"21","author":"P D\u2019Amelio","year":"2010","unstructured":"D\u2019Amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC (2010) Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int 21:1741\u20131750","journal-title":"Osteoporos Int"},{"key":"5701_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1359\/jbmr.071031","volume":"23","author":"P D\u2019Amelio","year":"2008","unstructured":"D\u2019Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G (2008) Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 23:373\u2013379","journal-title":"J Bone Miner Res"},{"key":"5701_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/ciia.2007.2.1.55","volume":"2","author":"S Migliaccio","year":"2007","unstructured":"Migliaccio S, Brama M, Spera G (2007) The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging 2:55\u201364","journal-title":"Clin Interv Aging"},{"key":"5701_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bone.2011.06.014","volume":"49","author":"P Leung","year":"2011","unstructured":"Leung P, Pickarski M, Zhuo Y, Masarachia PJ, Duong LT (2011) The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 49:623\u2013635","journal-title":"Bone"},{"key":"5701_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","volume":"25","author":"HG Bone","year":"2010","unstructured":"Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 25:937\u2013947","journal-title":"J Bone Miner Res"},{"key":"5701_CR13","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00198-016-3503-0","volume":"27","author":"R Rizzoli","year":"2016","unstructured":"Rizzoli R, Benhamou CL, Halse J, Miller PD, Reid IR, Rodr\u00edguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D (2016) Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. Osteoporos Int 27:2099\u20132107","journal-title":"Osteoporos Int"},{"key":"5701_CR14","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1210\/jc.2005-2602","volume":"91","author":"S Bonnick","year":"2006","unstructured":"Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SAM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631\u20132637","journal-title":"J Clin Endocrinol Metab"},{"key":"5701_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1742-1241.2008.01704.x","volume":"62","author":"DM Reid","year":"2008","unstructured":"Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME (2008) A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract 62:575\u2013584","journal-title":"Int J Clin Pract"},{"key":"5701_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S2213-8587(19)30346-8","volume":"7","author":"MR McClung","year":"2019","unstructured":"McClung MR, O\u2019Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster J-Y, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park J-G, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, Investigators LOFT (2019) Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol 7:899\u2013911","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5701_CR17","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMp1202619","volume":"366","author":"M Whitaker","year":"2012","unstructured":"Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 366:2048\u20132051","journal-title":"N Engl J Med"},{"key":"5701_CR18","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med 366:2051\u20132053","journal-title":"N Engl J Med"},{"key":"5701_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jbmr.212","volume":"26","author":"JA Eisman","year":"2011","unstructured":"Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, Santora AC, Ince BA, Lombardi A (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242\u2013251","journal-title":"J Bone Miner Res"},{"key":"5701_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s001980050093","volume":"8","author":"AC Looker","year":"1998","unstructured":"Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468\u2013489","journal-title":"Osteoporos Int"},{"key":"5701_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"5701_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"D Dempster","year":"2013","unstructured":"Dempster D, Compston JE, Drezner MK, Glorieux F, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized, nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2\u201317","journal-title":"J Bone Miner Res"},{"key":"5701_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2307\/2531248","volume":"42","author":"SL Zeger","year":"1986","unstructured":"Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121\u2013130","journal-title":"Biometrics"},{"key":"5701_CR24","doi-asserted-by":"publisher","first-page":"4602129","DOI":"10.1155\/2017\/4602129","volume":"2017","author":"G Golds","year":"2017","unstructured":"Golds G, Houdek D, Arnason T (2017) Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Endocrinol 2017:4602129","journal-title":"Int J Endocrinol"},{"key":"5701_CR25","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599\u20132607","journal-title":"J Clin Endocrinol Metab"},{"key":"5701_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610","journal-title":"N Engl J Med"},{"key":"5701_CR27","unstructured":"Duong LT, Pickarsky M, Clark S, Giezek H, Cohn D, Massaad R, Stoch SA (2016) Differential effects of odanacatib therapy on markers of bone resorption and formation in postmenopausal women with osteoporosis: a subgroup study of the 5-year data from the extension of the phase 3 Long-term Odanacatib Fracture Trial (LOFT). American Society for Bone and Mineral Research (ASBMR), 2016 September 16\u201319, Atlanta, Georgia, USA. Abstract SA0299"},{"key":"5701_CR28","doi-asserted-by":"crossref","unstructured":"Recker R, Dempster D, Langdahl B, Giezek H, Clark S, Ellis G, de Villiers T, Valter I, Zerbini CAF, Cohn D, Santora A, Duong LT (2020) Effects of odanacatib on bone structure and quality in postmenopausal women with osteoporosis: 5-year data from the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its extension. J Bone Miner Res 35(7):1289\u20131299.","DOI":"10.1002\/jbmr.3994"},{"key":"5701_CR29","first-page":"669","volume":"15","author":"A Mullard","year":"2016","unstructured":"Mullard A (2016) Merck & Co. drops osteoporosis drug odanacatib. Nat Rev Drug Discov 15:669","journal-title":"Nat Rev Drug Discov"},{"key":"5701_CR30","doi-asserted-by":"publisher","first-page":"e0156068","DOI":"10.1371\/journal.pone.0156068","volume":"11","author":"K Barnard","year":"2016","unstructured":"Barnard K, Lakey WC, Batch BC, Chiswell K, Tasneem A, Green JB (2016) Recent clinical trials in osteoporosis: a firm foundation or falling short? PLoS One 11:e0156068","journal-title":"PLoS One"},{"key":"5701_CR31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719\u2013725","journal-title":"J Bone Miner Res"},{"key":"5701_CR32","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714\u20131723","journal-title":"N Engl J Med"},{"key":"5701_CR33","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbjaerg CS, Ho PR et al (2015) A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab 100:1335\u20131342","journal-title":"J Clin Endocrinol Metab"},{"key":"5701_CR34","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161\u20133169","journal-title":"J Clin Endocrinol Metab"},{"key":"5701_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317","journal-title":"J Bone Miner Res"},{"key":"5701_CR36","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellstr\u00f6m D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05701-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-020-05701-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05701-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T13:26:00Z","timestamp":1697117160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-020-05701-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5701"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05701-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BBS, HG, and ACS are, or were at the time of study conduct, employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and may own stock and\/or stock options in the company. NB has received research support from Radius and is a consultant for Amgen. RC has been a consultant and\/or has given talks for AbbVie, Amgen, Bristol-Myers Squibb, Chugai, Janssen-Cilag, Lilly, MSD, Pfizer, Radius, Sandoz, and UCB. BLL has received research grants (institution) from Amgen and Novo Nordisk and has been involved in advisory boards and lecturing for Amgen, Eli Lilly, MSD, and UCB. EO has received research support from Lilly and Mereo and provides consulting for Bayer and Amgen. ACS is currently a consultant and Chief Medical Officer of Entera Bio Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent before any study procedure was initiated.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}